)
Elite Pharmaceuticals (ELTP) investor relations material
Elite Pharmaceuticals Q2 2027 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q2 FY2027 revenue rose 10.4% YoY to $40.1M; operating income increased 21% to $9.9M and net income attributable to common shareholders was $17.3M.
H1 revenue fell 5% to $72.4M, while net income rose to $23.2M from $7.8M, aided by a $9.8M non-cash warrant fair-value gain.
H1 gross margin fell to 41% from 54% amid lower net prices and competition; priorities include pipeline and facility expansion and a Nasdaq listing targeted for March 2027.
Financial highlights
Q2 revenue was $40.1M versus $36.3M; gross profit rose to $16.0M from $14.1M, and operating income increased to $9.9M from $8.2M.
H1 gross profit decreased to $29.5M from $41.3M and operating income was $17.5M versus $29.9M; income before tax increased to $27.5M from $15.1M.
H1 R&D expense increased 35% to $1.9M; operating cash flow was $7.0M versus $19.9M, with prior-year cash flow benefiting from stronger Lisdex margins before market correction.
H1 investing cash outflow was $1.5M, primarily for property and equipment; financing cash outflow was $0.4M, primarily finance-lease principal.
Outlook and guidance
Management expects an approvable status for the filed anticoagulant in 2027, with launch targeted for 2028; its FDA GDUFA date is March 2027.
A second anticoagulant is in advanced development, with a bioequivalence study expected in H1 2027 and approval anticipated in 2028, subject to expectations being met.
At least one type 2 diabetes bioequivalence study is planned for H1 2027; the diabetes pipeline grew from three formulations to four.
An anticonvulsant ANDA filing is targeted for Q1 2027, pending stability data; positive pivotal bioequivalence results were reported for an undisclosed anticonvulsant candidate.
Strategy emphasizes approved generics, additional ANDAs, pipeline candidates, licensing and co-development; Nasdaq listing is targeted for March 2027, subject to shareholder elections and application steps.
- Revenue and operating income fell year over year, while product volumes and pipeline launches advanced.ELTP
Q1 2027 - Revenue up 77% and operating income up 151% year-over-year, fueled by new product launches.ELTP
Q4 2026 - Revenue and profit more than doubled, driven by new generics and strong market share.ELTP
Q3 2026 - Revenue up 92% to $36.3M, net income $13.7M, driven by new launches and strong cash flow.ELTP
Q2 2026 - Revenue and profit surged, but a $22.1M warrant expense led to a net loss.ELTP
Q1 2026 - Revenue up 33% to $18.9M, but non-cash warrant expense drove a net loss.ELTP
Q2 2025 - Revenue up 109% to $18.8M; operating income and profit surged despite non-cash warrant expense.ELTP
Q1 2025 - Revenue up 65% to $56.6M, operating profit $10.8M, targeting $70M next year.ELTP
Q4 2024 - Nine-month revenue up 35% to $52M, but Q3 profit fell on shipment delays and warrant revaluation.ELTP
Q3 2025
Next Elite Pharmaceuticals earnings date
Next Elite Pharmaceuticals earnings date
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
)
)